Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Back

ESC Professional Premium Access

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Session: Lipids - Drug therapy 1

Topic: Drug therapy

Speaker: Mr T. Michaeli (Mannheim, DE) Mr D. Michaeli (Mannheim, DE)

Event: ESC Congress 2022

Congress Presentation

About the speakers

Mr Thomas Michaeli

Mannheim (Germany)

1 presentation

0 follower

Mr Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

1 presentation

0 follower

5 more presentations in this session

Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia

Speaker: Doctor I. Andrikou (Athens, GR)

Access

Abstract

Slides

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Speaker: Doctor R. Rosenson (New York, US)

Access

Abstract

Slides

Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

Speaker: Doctor A. Bilitou (Munich, DE)

Access

Abstract

Slides

PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study

Speaker: Doctor C. Basile (Naples, IT)

Access

Abstract

Slides

Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis

Speaker: Doctor T. Osadnik (Zabrze, PL)

Access

Abstract

Slides

Access the full session

Lipids - Drug therapy 1

Speakers: Mr T. Michaeli, Mr D. Michaeli, Doctor I. Andrikou, Doctor R. Rosenson, Doctor A. Bilitou...

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

About the speakers

Mr Thomas Michaeli

Mr Daniel Tobias Michaeli

5 more presentations in this session

Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study

Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis

Access the full session

Lipids - Drug therapy 1

About the event

ESC Congress 2022

ESC 365 is supported by